Metagenomi Highlights Q1 Progress on MGX-001 Gene Therapy

Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Metagenomi, Inc. ( (MGX) ) has shared an announcement. Metagenomi Therapeutics reported first quarter 2026 results on May 11, 2026, highlighting progress on its MGX-001 hemophilia A program and platform technologies while maintaining a cash position of $140.2 million, which it expects will fund operations through the fourth quarter of 2027. The company reduced R&D and G&A expenses versus the prior year, advanced plans for a fourth-quarter 2026 regulatory submission to support a global clinical program and 2027 trial initiation, and bolstered its scientific credentials with a Nature Structural & Molecular Biology publication on its compact CRISPR nuclease MG119-28, underscoring its ambition to deliver one-time, potentially curative treatments. Metagenomi also reported in vivo proof-of-concept in non-human primates for its MGX-001 large gene integration system and is pursuing additional indications suited to protein replacement via gene insertion, signaling a broader pipeline strategy beyond hemophilia A. The appointment of hematologist and industry veteran Kapil Saxena, MD to lead MGX-001 clinical development further strengthens its clinical execution capabilities, while a decline in collaboration revenue and lower expenses frame a transition toward internally driven programs that could reshape its position in the competitive genome-editing landscape if upcoming regulatory milestones are met. The most recent analyst rating on (MGX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Metagenomi, Inc. stock, see the MGX Stock Forecast page. Spark’s Take on MGX Stock According to Spark, TipRanks’ AI Analyst, MGX is a Neutral. Score is held back primarily by persistent large losses and significant cash burn with declining equity, indicating elevated funding and execution risk. Technicals are neutral-to-mixed (short-term improvement but long-term downtrend), while valuation is difficult to support given negative earnings and no dividend. Corporate updates are constructive, especially the extended runway and pipeline milestones, but do not offset weak financial performance. To see Spark’s full report on MGX stock, click here. More about Metagenomi, Inc. Metagenomi Therapeutics, Inc. is an in vivo genome editing company developing curative genetic medicines using proprietary CRISPR-based tools derived from metagenomics to correct diverse genetic mutations across the human genome. The company targets high-value indications with well-understood biology and clear regulatory pathways, led by its wholly owned MGX-001 program for hemophilia A and partnered assets in cardiometabolic diseases. Average Trading Volume: 207,207 Technical Sentiment Signal: Sell Current Market Cap: $53.04M